321 related articles for article (PubMed ID: 31379000)
1. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score.
Sanfilippo KM; Luo S; Wang TF; Fiala M; Schoen M; Wildes TM; Mikhael J; Kuderer NM; Calverley DC; Keller J; Thomas T; Carson KR; Gage BF
Am J Hematol; 2019 Nov; 94(11):1176-1184. PubMed ID: 31379000
[TBL] [Abstract][Full Text] [Related]
2. Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma.
Li A; Wu Q; Luo S; Warnick GS; Zakai NA; Libby EN; Gage BF; Garcia DA; Lyman GH; Sanfilippo KM
J Natl Compr Canc Netw; 2019 Jul; 17(7):840-847. PubMed ID: 31319391
[TBL] [Abstract][Full Text] [Related]
3. Assessing the risk of venous thromboembolism in multiple myeloma.
Sanfilippo KM
Thromb Res; 2020 Jul; 191 Suppl 1():S74-S78. PubMed ID: 32736783
[TBL] [Abstract][Full Text] [Related]
4. Validation of the IMPEDE VTE score for prediction of venous thromboembolism in Chinese patients with multiple myeloma: A single-center retrospective cohort study.
Bao L; Fang LJ; Xiao MY; Lu MQ; Chu B; Shi L; Gao S; Xiang QQ; Wang YT; Liu X; Ding YH; Xin Z; Chen Y; Wang MZ; Hu WK; Guo CY; Chen LY; Sun K
Thromb Res; 2024 Apr; 236():130-135. PubMed ID: 38430904
[TBL] [Abstract][Full Text] [Related]
5. Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
Bradbury CA; Craig Z; Cook G; Pawlyn C; Cairns DA; Hockaday A; Paterson A; Jenner MW; Jones JR; Drayson MT; Owen RG; Kaiser MF; Gregory WM; Davies FE; Child JA; Morgan GJ; Jackson GH
Blood; 2020 Aug; 136(9):1091-1104. PubMed ID: 32438407
[TBL] [Abstract][Full Text] [Related]
6. Comparison of three risk assessment models for thromboembolism in multiple myeloma patients receiving immunomodulators: a Brazilian historical cohort.
da Costa IHF; de Pádua CAM; de Miranda Drummond PL; Silveira LP; Malta JS; Dos Santos RMM; Reis AMM
J Thromb Thrombolysis; 2023 Jul; 56(1):147-155. PubMed ID: 37133703
[TBL] [Abstract][Full Text] [Related]
7. Heparin versus aspirin thromboprophylaxis adds independent value to IMPEDE-VTE score for venous thrombosis prediction in multiple myeloma.
Bravo-Perez C; Fernández-Caballero M; Soler-Espejo E; Garcia-Torralba E; Sorigue M; García-Malo MD; Jerez A; Vicente V; Roldán V; de Arriba F
J Thromb Thrombolysis; 2021 Oct; 52(3):848-853. PubMed ID: 33649980
[TBL] [Abstract][Full Text] [Related]
8. External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs.
Dima D; Li A; Granat LM; Dhillon P; Chamseddine F; Yalamanchali A; Mirzai S; Wei W; Samaras CJ; Valent J; Anwer F; Khouri J
Br J Haematol; 2023 Apr; 201(2):280-284. PubMed ID: 36604838
[TBL] [Abstract][Full Text] [Related]
9. Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study.
Covut F; Ahmed R; Chawla S; Ricaurte F; Samaras CJ; Anwer F; Garcia AVM; Angelini DE; Mazzoni S; Faiman B; Valent J; Khouri J
Br J Haematol; 2021 Jun; 193(6):1213-1219. PubMed ID: 33997961
[TBL] [Abstract][Full Text] [Related]
10. Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database.
Palmaro A; Rougé-Bugat ME; Gauthier M; Despas F; Moulis G; Lapeyre-Mestre M
Pharmacoepidemiol Drug Saf; 2017 May; 26(5):578-586. PubMed ID: 28198064
[TBL] [Abstract][Full Text] [Related]
11. Application of risk factors for venous thromboembolism in patients with multiple myeloma starting chemotherapy, a real-world evaluation.
Baker HA; Brown AR; Mahnken JD; Shireman TI; Webb CE; Lipe BC
Cancer Med; 2019 Jan; 8(1):455-462. PubMed ID: 30585435
[TBL] [Abstract][Full Text] [Related]
12. Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM/DFCI 2009 cohort.
Chalayer E; Talbot A; Frenzel L; Karlin L; Collet P; Guyotat D; Attal M; Leleu X; Tardy B
J Thromb Haemost; 2022 Aug; 20(8):1859-1867. PubMed ID: 35557490
[TBL] [Abstract][Full Text] [Related]
13. Predicting the risk of venous thromboembolism in newly diagnosed myeloma with immunomodulatory drugs: External validation of the IMPEDE VTE score.
Chalayer E; Teste A; Guyotat D; Elalamy I; Leleu X; Tardy B
Am J Hematol; 2020 Jan; 95(1):E18-E20. PubMed ID: 31617240
[No Abstract] [Full Text] [Related]
14. Development and validation of a new risk assessment model for immunomodulatory drug-associated venous thrombosis among Chinese patients with multiple myeloma.
Li X; Sun X; Fang B; Leng Y; Sun F; Wang Y; Wang Q; Jin J; Yang M; Xu B; Fang Z; Chen L; Chen Z; Yang Q; Zhang K; Ye Y; Geng H; Sun Z; Hao D; Huang H; Wang X; Jing H; Ma L; Pan X; Chen W; Li J
Thromb J; 2023 Oct; 21(1):105. PubMed ID: 37794471
[TBL] [Abstract][Full Text] [Related]
15. Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy.
Covut F; Sanfilippo KM
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):363-367. PubMed ID: 36485142
[TBL] [Abstract][Full Text] [Related]
16. Quality Improvement at an Academic Cancer Center: Venous Thromboembolism Prophylaxis in Patients With Multiple Myeloma.
Baz R; Furman R; Simondsen K; Stone C
Cancer Control; 2020; 27(2):1073274820930204. PubMed ID: 32551873
[TBL] [Abstract][Full Text] [Related]
17. Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.
Piedra K; Peterson T; Tan C; Orozco J; Hultcrantz M; Hassoun H; Mailankody S; Lesokhin A; Shah U; Lu S; Patel D; Derkach A; Wilkins CR; Korde N
Br J Haematol; 2022 Jan; 196(1):105-109. PubMed ID: 34396516
[TBL] [Abstract][Full Text] [Related]
18. Hematologists' awareness of venous thromboembolism in multiple myeloma: a national survey in China.
Li Q; Zhang B; Cheng Q; Zhao F; Li J; Yan H; Xu A; Sun C; Hu Y
Ann Med; 2023; 55(2):2263019. PubMed ID: 37983471
[TBL] [Abstract][Full Text] [Related]
19. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review.
Al-Ani F; Bermejo JM; Mateos MV; Louzada M
Thromb Res; 2016 May; 141():84-90. PubMed ID: 26986753
[TBL] [Abstract][Full Text] [Related]
20. Thrombotic Risk and Calculated Whole Blood Viscosity in a Cohort of Patients With New Diagnosis of Multiple Myeloma.
Carlisi M; Presti RL; Mancuso S; Siragusa S; Caimi G
Clin Appl Thromb Hemost; 2024; 30():10760296231222477. PubMed ID: 38173275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
